Targeted panel sequencing enriches the targeted DNA region followed by high-throughput DNA sequencing. Through studying a large number of samples at targeted regions, cancer-related gene variants can be identified and validated for clinical diagnosis and drug development.
(1) Guided information: Focusing on targeted genomic regions.
(2) High accuracy: Focused sequencing in targeted regions for better coverage and higher accuracy; improved detection sensitivity for rare variants.
(3) Cost-effective and efficient: Higher throughput, especially for large sample size studies.
(4) Faster: Shortened research period, speeding up study publication and accelerating clinical applications.
•Sample types: DNA;
•Sample amount: >=1.0 ug DNA (extracted from fresh or frozen samples);
•>= 1.5 ug DNA (extracted from FFPE samples);
•Sample concentration: >=20 ng/ul;
•Capture platforms: Agilent SureSelect Kit;
•Sequencing platform: HiSeq X™ Ten；
•Sequencing depth: carcinoma tissue (500 x), normal tissue/blood samples (250x),
•Turnaround time: 42 days.